Micofenolat Mofetil Stada

Mycophenolate Mofetil, the active ingredient in Micofenolat Mofetil Stada, is an antimetabolite immunosuppressant presented as an oral formulation for oral use. It is employed to prevent organ transplant rejection, treat lupus nephritis, and reduce the risk of graft‑versus‑host disease in appropriate patients.

GNH USA supplies Micofenolat Mofetil Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution. Customers benefit from reliable supply chains and responsive technical support.

Mycophenolate Mofetil is an antimetabolite immunosuppressant used to modulate immune activity in several transplant‑related and autoimmune conditions, where it inhibits lymphocyte proliferation.

- Organ transplant rejection: helps prevent acute and chronic rejection by suppressing lymphocyte proliferation. - Lupus nephritis: reduces renal inflammation and proteinuria in patients with systemic lupus erythematosus. - Graft‑versus‑host disease: decreases the incidence and severity of GVHD following hematopoietic stem cell transplantation. - Kidney transplantation: aids in maintaining graft function by preventing immune‑driven injury. - Liver transplantation: contributes to reduced incidence of acute rejection episodes.

Mycophenolate Mofetil may cause a range of adverse reactions, from mild to severe. Patients should be monitored regularly for any emerging symptoms.

Common Side Effects: - Nausea and vomiting - Diarrhea or abdominal discomfort - Headache - Hypertension - Mild infections of the upper respiratory tract

Serious or Rare Side Effects: - Leukopenia or severe neutropenia - Anemia or thrombocytopenia - Opportunistic infections (e.g., CMV, PCP) - Hepatic dysfunction or elevated transaminases - Malignancies such as post‑transplant lymphoproliferative disorder

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor relevant parameters throughout treatment.

- Dose adjustment in renal impairment: reduce dose according to renal function. - Monitor blood counts: regular CBC to detect leukopenia or anemia. - Assess liver function: periodic LFTs for hepatic toxicity. - Avoid in pregnancy: category D, use only if benefits outweigh risks. - Vaccinations: live vaccines contraindicated during therapy. - Store at ambient temperature: keep below 25 °C, protect from moisture and light.

Mycophenolate Mofetil can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Live vaccines: may cause infection. - Antacids containing magnesium or aluminum: reduce absorption. - Azathioprine: additive bone marrow suppression. - Strong CYP3A4 inducers (e.g., rifampin): markedly decrease exposure.

Moderate Interactions (Monitor Closely): - Cyclosporine: increased mycophenolate levels, monitor renal function. - Tacrolimus: may increase mycophenolate exposure, adjust dose if needed. - Warfarin: potential alteration of INR, monitor coagulation.